Dechra
Dechra Pharmaceuticals PLC, commonly known as Dechra, is a leading global veterinary pharmaceutical company headquartered in the United Kingdom. Founded in 1997, Dechra has established a strong presence in Europe, North America, and Australia, focusing on the development and marketing of high-quality products for companion animals and livestock. Specialising in veterinary medicines, Dechra offers a diverse range of core products, including anaesthetics, dermatology treatments, and nutritional supplements. What sets Dechra apart is its commitment to innovation and quality, ensuring that its products meet the highest standards of safety and efficacy. With a robust market position, Dechra has achieved significant milestones, including numerous product launches and strategic acquisitions, solidifying its reputation as a trusted partner in animal health. The company continues to lead the way in veterinary pharmaceuticals, dedicated to improving the health and well-being of animals worldwide.
DitchCarbon Score
How does Dechra's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Dechra's score of 42 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Dechra's reported carbon emissions
In 2022, Dechra Pharmaceuticals PLC reported total greenhouse gas emissions of approximately 14,375,000 kg CO2e globally, with emissions broken down into 6,709,000 kg CO2e for Scope 1, 4,896,000 kg CO2e for Scope 2, and 2,770,000 kg CO2e for Scope 3. In the UK, the company recorded emissions of about 1,241,901 kg CO2e, comprising 489,757 kg CO2e from Scope 1, 607,104 kg CO2e from Scope 2, and 144,040 kg CO2e from Scope 3. Dechra has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions across its value chain by 2050. The company has established near-term targets to reduce absolute Scope 1 and 2 emissions by 42% by 2030, using 2021 as the baseline year. Additionally, it aims to reduce Scope 3 emissions by 51.6% per GBP value added within the same timeframe. Long-term goals include a 90% reduction in Scope 1 and 2 emissions and a 97% reduction in Scope 3 emissions by 2050. These targets align with the Science Based Targets initiative (SBTi) and reflect Dechra's commitment to addressing climate change within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 6,747,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 4,969,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 2,347,000 | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Dechra is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
